Oppenheimer Starts Cybin Inc. (CYBN) at Outperform

October 4, 2021 4:05 PM EDT
Get Alerts CYBN Hot Sheet
Price: $2.00 +2.04%

Rating Summary:
    3 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 8 | Down: 14 | New: 47
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Oppenheimer analyst Francois Brisebois initiates coverage on Cybin Inc. (NYSE: CYBN) with a Outperform rating and a price target of $7.00.

The analyst commented, "Led by a proven management team, we believe CYBN's scalability potential and calculated approach warrant a deeper dive. Its most advanced product, CYB001, consists of sublingual psilocybin for patients with major depressive disorder (MDD). In addition to the extensive literature supporting psilocybin's efficacy, we are encouraged by CYBN's delivery system as it offers potential for faster onset and improved bioavailability. Phase 2a is expected to begin soon with P2b results potentially by CYE22. Although CYB001 is further along, we view CYB003 for alcohol use disorder (AUD), another large unmet need, as the main reason to own CYBN. This orally-disintegrating tablet of deuterated tryptamine could be shorter-acting than CYB001. Finally, we view CYBN's technology efforts into digital assisted psychotherapy and real-time neuroimaging as attractive call options."

For an analyst ratings summary and ratings history on Cybin Inc. click here. For more ratings news on Cybin Inc. click here.

Shares of Cybin Inc. closed at $2.19 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Hot Comments, Hot New Coverage, New Coverage